13-Mar-2026
Globe Newswire (Thu, 12-Mar 9:00 AM ET)
Globe Newswire (Wed, 11-Mar 9:00 AM ET)
Trinity Biotech Reports Major Technical Breakthroughs in Next-Generation CGM+ Platform
TipRanks (Tue, 10-Mar 8:24 AM ET)
Trinity Biotech Flags Lower Q4 2025 Revenue as It Accelerates Manufacturing Shift and Growth Plan
TipRanks (Tue, 10-Mar 8:24 AM ET)
Globe Newswire (Tue, 10-Mar 7:55 AM ET)
Trinity Biotech Provides Business and Trading Update
Globe Newswire (Tue, 10-Mar 7:45 AM ET)
Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives
Globe Newswire (Wed, 25-Feb 9:00 AM ET)
Globe Newswire (Fri, 20-Feb 5:00 PM ET)
Globe Newswire (Fri, 13-Feb 5:00 PM ET)
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Trinity Biotech PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol TRIB.
As of March 13, 2026, TRIB stock price climbed to $0.77 with 774,304 million shares trading.
TRIB has a beta of 2.71, meaning it tends to be more sensitive to market movements. TRIB has a correlation of 0.21 to the broad based SPY ETF.
TRIB has a market cap of $14.32 million. This is considered a Sub-Micro Cap stock.
Last quarter Trinity Biotech PLC - American Depositary Shares reported $11 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.12.
In the last 3 years, TRIB traded as high as $6.20 and as low as $.48.
TRIB has underperformed the market in the last year with a return of +12.6%, while the SPY ETF gained +21.4%. In the last 3 month period, TRIB fell short of the market, returning -28.5%, while SPY returned -2.6%. However, in the most recent 2 weeks TRIB has outperformed the stock market by returning +6.3%, while SPY returned -3.5%.
TRIB support price is $.65 and resistance is $.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRIB shares will trade within this expected range on the day.